Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Regeneron Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$62.78B | 14.2x | 0.75 | US$594.32 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 37.1% Upside | Upgrade to Pro+ | |
Lonza Group AG | OTC Markets | Healthcare | Biotechnology & Medical Research | US$48.10B | 58x | US$68.72 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.8% Upside | Upgrade to Pro+ | ||
argenx ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | US$34.21B | 31.7x | 0.08 | US$565.63 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.6% Upside | Upgrade to Pro+ | |
IQVIA Holdings | NYSE | Healthcare | Biotechnology & Medical Research | US$24.67B | 19.3x | 74.53 | US$142.82 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.6% Upside | Upgrade to Pro+ | |
BeiGene ADS | NASDAQ | Healthcare | Biotechnology & Medical Research | US$24.40B | -60.7x | -1.25 | US$228.38 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 47.5% Upside | Upgrade to Pro+ | |
BioNTech | NASDAQ | Healthcare | Biotechnology & Medical Research | US$22.20B | -26.1x | 0.03 | US$92.77 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39% Upside | Upgrade to Pro+ | |
Summit Therapeutics PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | US$17.15B | -82.2x | 0.7 | US$23.87 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Insmed | NASDAQ | Healthcare | Biotechnology & Medical Research | US$12.43B | -11.6x | 0.9 | US$68.12 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42.2% Upside | Upgrade to Pro+ | |
Exelixis | NASDAQ | Healthcare | Biotechnology & Medical Research | US$12.36B | 20.1x | 0.11 | US$45.39 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -13.5% Downside | Upgrade to Pro+ | |
Genmab AS | NASDAQ | Healthcare | Biotechnology & Medical Research | US$12.26B | 10.7x | 0.12 | US$19.88 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.3% Upside | Upgrade to Pro+ | |
WuXi Biologics | OTC Markets | Healthcare | Biotechnology & Medical Research | US$12.24B | 27.3x | 16.85 | US$3 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Wuxi Biologics | OTC Markets | Healthcare | Biotechnology & Medical Research | US$12.24B | 27.3x | 16.85 | US$6 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Tempus AI | NASDAQ | Healthcare | Biotechnology & Medical Research | US$10.84B | -13.3x | 2.34 | US$65.48 | 4.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3.8% Upside | Upgrade to Pro+ | |
EXACT Sciences | NASDAQ | Healthcare | Biotechnology & Medical Research | US$10.65B | -10.4x | 0.03 | US$56.44 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.1% Upside | Upgrade to Pro+ | |
ICON PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | US$10.45B | 14.4x | 1.22 | US$131.63 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.3% Upside | Upgrade to Pro+ | |
Moderna | NASDAQ | Healthcare | Biotechnology & Medical Research | US$9.58B | -2.9x | -0.06 | US$24.86 | 5.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.3% Upside | Upgrade to Pro+ | |
Ascendis Pharma AS | NASDAQ | Healthcare | Biotechnology & Medical Research | US$9.51B | -26.1x | -0.69 | US$157.60 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.3% Upside | Upgrade to Pro+ | |
Qiagen | NYSE | Healthcare | Biotechnology & Medical Research | US$9.24B | 98.7x | -1.33 | US$42.65 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.7% Upside | Upgrade to Pro+ | |
Medpace Holdings | NASDAQ | Healthcare | Biotechnology & Medical Research | US$8.79B | 22.6x | 0.61 | US$305.74 | 3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -2.1% Downside | Upgrade to Pro+ | |
Bio-Techne | NASDAQ | Healthcare | Biotechnology & Medical Research | US$7.70B | 59.1x | -1.75 | US$49.15 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42.9% Upside | Upgrade to Pro+ | |
Revolution Med | NASDAQ | Healthcare | Biotechnology & Medical Research | US$7.39B | -9.9x | 1.29 | US$39.50 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Charles River Laboratories | NYSE | Healthcare | Biotechnology & Medical Research | US$6.94B | -228.6x | 2.01 | US$140.97 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.6% Upside | Upgrade to Pro+ | |
Blueprint Medicines Corp | NASDAQ | Healthcare | Biotechnology & Medical Research | US$6.59B | -41.4x | -0.84 | US$101.71 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.1% Upside | Upgrade to Pro+ | |
Madrigal Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$6.46B | -16.1x | -0.74 | US$291 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 43.4% Upside | Upgrade to Pro+ | |
Verona Pharma ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | US$6.34B | -32.8x | 0.24 | US$71.45 | 2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34.5% Upside | Upgrade to Pro+ | |
Telix Pharmaceuticals ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | US$5.63B | 190.5x | 0.23 | US$16.68 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42.5% Upside | Upgrade to Pro+ | |
Regencell Bioscience Holdings | NASDAQ | Healthcare | Biotechnology & Medical Research | US$5.46B | -1,190x | -41.42 | US$393 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ionis Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$5.34B | -11.2x | 0.93 | US$33.58 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Nuvalent | NASDAQ | Healthcare | Biotechnology & Medical Research | US$5.27B | -16.6x | 0.2 | US$73.37 | 3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 49.9% Upside | Upgrade to Pro+ | |
Alkermes Plc | NASDAQ | Healthcare | Biotechnology & Medical Research | US$5.18B | 14.4x | -0.8 | US$31.42 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.2% Upside | Upgrade to Pro+ | |
Legend Bio | NASDAQ | Healthcare | Biotechnology & Medical Research | US$5.11B | -23.3x | -0.49 | US$27.78 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Vaxcyte | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.99B | -8.1x | -1.4 | US$31.85 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
PureTech Health | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.98B | 78.9x | 0.04 | US$16.59 | -4.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Krystal Biotech | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.78B | 30.3x | 0.28 | US$130.69 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Soleno Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.77B | -16.1x | 0.18 | US$75.01 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.8% Upside | Upgrade to Pro+ | |
ACADIA | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.76B | 16.1x | 0 | US$22.26 | 26.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.8% Upside | Upgrade to Pro+ | |
Cytokinetics Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.70B | -5.9x | -3.19 | US$31 | 3.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Crispr Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.35B | -8.6x | 0.12 | US$38.78 | 6.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Arcellx | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.22B | -19.2x | 0.1 | US$58.78 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Viking Therapeutics Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.19B | -24.5x | 1.01 | US$28.43 | 3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alvotech | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.16B | 31x | 0.26 | US$10.46 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 43.8% Upside | Upgrade to Pro+ | |
Akero Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$3.09B | -10.4x | 0.42 | US$38.88 | -2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Crinetics Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.94B | -8.2x | 6.28 | US$31.24 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Scholar Rock | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.92B | -11.1x | 0.58 | US$30.51 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merus | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.89B | -10x | 0.2 | US$41.54 | 3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Protagonist Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.77B | 50x | -0.7 | US$44.49 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Metsera | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.69B | -2.9x | 0.04 | US$29.52 | 15.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Immunitybio Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.50B | -5.2x | -0.1 | US$2.84 | 6.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Immunovant | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.46B | -5.5x | 0.14 | US$14.46 | 3.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
MoonLake Immunotherapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$2.39B | -16.3x | 0.13 | US$37.62 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |